Skip to main content
Smart Investors Daily
SA

NASDAQ · SANA

Sana Biotechnology, Inc.

Healthcare · Biotechnology

$2.02

Down-$0.14 (-6.93%)

Updated Nov 17, 2026, 1:40 AM

SID Score

4.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.33B
P/E ratio
-4.72
Dividend yield
0.00%
52-week range
$1.86 – $4.22
Volume
3.2M
Avg. volume
5.83M

Price performance · SANA

SANA price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 13, 2026

SANA closed at $2.02 after 20 trading sessions, down 12.17% for the selected period.

Last close
$2.02
Period change
-12.17%
Period low
$2.01
Period high
$2.72
Daily close
View OHLC price history
SANA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 13, 2026$2.05$2.05$1.8601$2.023.2M
Nov 12, 2026$2.25$2.25$2.00$2.013.69M
Nov 11, 2026$2.43$2.449$2.28$2.292.73M
Nov 10, 2026$2.42$2.52$2.31$2.432.54M
Nov 9, 2026$2.42$2.48$2.28$2.4653.26M
Nov 6, 2026$2.49$2.49$2.2825$2.372.31M
Nov 5, 2026$2.53$2.53$2.28$2.343.09M
Nov 4, 2026$2.55$2.62$2.455$2.562.64M
Nov 3, 2026$2.43$2.52$2.40$2.441.82M
Nov 2, 2026$2.57$2.585$2.37$2.402.6M
Oct 30, 2026$2.68$2.72$2.51$2.572.08M
Oct 29, 2026$2.655$2.7678$2.65$2.723.31M
Oct 28, 2026$2.43$2.64$2.38$2.633.29M
Oct 27, 2026$2.37$2.48$2.33$2.472.62M
Oct 26, 2026$2.33$2.385$2.29$2.361.51M
Oct 23, 2026$2.35$2.38$2.245$2.331.71M
Oct 22, 2026$2.325$2.44$2.28$2.372.43M
Oct 21, 2026$2.38$2.39$2.315$2.352.4M
Oct 20, 2026$2.27$2.42$2.25$2.363.53M
Oct 19, 2026$2.32$2.3588$2.22$2.302.63M

Latest SANA news

The latest Smart Investors Daily articles mentioning SANA.

SANA research

Overview

Company profile and research snapshot.

Company profile

Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$8.00
Implied upside
—
Analysts
15
SANA recent ratings
DateFirmRatingTarget
Aug 14, 2026B of A SecuritiesBuy—
Apr 14, 2026WedbushOutperform—
Mar 4, 2026HC Wainwright & Co.Buy—
Jan 6, 2026B of A SecuritiesBuy—
Nov 7, 2025WedbushOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 5, 2026

Sana: Q3 Earnings Snapshot

SEATTLE (AP) — SEATTLE (AP) — Sana Biotechnology Inc. (SANA) on Thursday reported third-quarter earnings of $20.

Yahoo · Nov 5, 2026

Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates

Continued progress toward starting SC451 Phase 1/2 trial in type 1 diabetes Continued progress toward starting clinical study for SG293 in non-Hodgkin lymphoma Announced follow-on publication in The New England Journal of Medicine (NEJM) highlighting long-term data and durability of hypoimmune-modified islet cell transplantation with UP421 without immunosuppression in type 1 diabetes Advancing strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and accelerating

SeekingAlpha · Oct 13, 2026

Sana Biotechnology: A Shot At Diabetes

Sana Biotechnology trades at a steep discount despite promising T1D assets UP421 and SC451. Check out why SANA stock is a buy.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.